StockGlow

Biodesix, Inc. (BDSX)

Blood tests that predict lung cancer risk and guide treatment decisions.

$21.03-0.05%Healthcare
Compare BDSX with
StockGlow Score
95
Bullish
BearishBullish
1 year ago+189.7%

The outlook

Biodesix trades at $21.03, positioned well above both its 50- and 200-day moving averages. All six analysts covering the stock rate it a Strong Buy, with an average price target about 47% above the current level. The stock sits near the upper end of its 52-week range, reflecting sustained upward momentum.

What’s behind the score

Analyst consensusStrong Buy — 1.0 avg of 6 analysts
Price trendAbove its 50- & 200-day averages
52-week range80% of the way from its 52-week low to high
Price targetAvg target +47% vs current price

Analyst price target

~12-month · 6 analysts
$30.83average target+46.6% vs now
Now $21.03
Low $26.00High $40.00

Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.

Market cap
$217.8M
52-wk high
$24.92
52-wk low
$5.26
50-day avg
$18.21
200-day avg
$12.47
Trailing P/E
—

Similar stocks

AFIBAcutus Medical, Inc.$0.00+0.00%ALGSAligos Therapeutics, Inc.$4.25+4.17%DMRADamora Therapeutics, Inc.$29.42-0.07%NMADNOMAD Power Solutions, Inc.$4.43-0.45%STTKShattuck Labs, Inc.$6.82-3.12%

The StockGlow Score is a snapshot of current, observable market data (analyst ratings, price trend, 52-week range) — not a prediction, forecast, or recommendation. Informational only, not investment advice. Data from public sources and may be delayed. How this works·Privacy